ArriVent BioPharma, Inc.
AVBP Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$21.00
9.4%What ArriVent BioPharma, Inc. does
No business description yet.
- Legal name
- ArriVent BioPharma, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Accession · CIK
- 0001104659-26-024127
0001868279
Revenue and margins
ArriVent BioPharma, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
ArriVent BioPharma, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 22.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably ArriVent BioPharma, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $150M | $219M | $313M |
| Current ratio | 13.8x | 13.1x | 12.8x |
| Quick ratio | 13.8x | 13.1x | 12.8x |
| Total assets | $163M | $275M | $333M |
| Total liabilities | $11.8M | $17.3M | $25.9M |
| Shareholders' equity | −$153M | $258M | $307M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✕ | ✕ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −8.3% | −4.7% | −1.9% |
| Altman Z'' | −13.89 | 15.52 | 10.94 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $64.9M | $79.0M | $153M |
| Operating income | −$74.6M | −$94.3M | −$178M |
| Net income | −$69.3M | −$80.5M | −$166M |
| Net income to common | −$69.3M | −$80.5M | −$166M |
| Diluted EPS | −$32.38 | −$2.56 | −$4.32 |
| Diluted shares | 0.00B | 0.03B | 0.04B |
| Cash flow | |||
| Cash from operations | −$55.8M | −$70.2M | −$161M |
| Depreciation and amortization | — | — | −$3.0M |
| Stock-based compensation | $0.9M | $3.2M | $12.5M |
| Balance sheet | |||
| Cash and short-term investments | $150M | $219M | $313M |
| Current assets | $160M | $227M | $333M |
| Current liabilities | $11.6M | $17.3M | $25.9M |
| Total assets | $163M | $275M | $333M |
| Total liabilities | $11.8M | $17.3M | $25.9M |
| Shareholders' equity | −$153M | $258M | $307M |
| Returns | |||
| Return on capital employed | −49.2% | −36.6% | −57.8% |
| Return on equity | — | −154.1% | −58.9% |
| Return on assets | −42.5% | −36.7% | −54.7% |
| Return on tangible equity | — | −31.2% | −54.1% |
| Growth | |||
| Share count change | — | 1,369.8% | 22.2% |
| Financial health | |||
| Current ratio | 13.8x | 13.1x | 12.8x |
| Quick ratio | 13.8x | 13.1x | 12.8x |
| Quality scores | |||
| Altman Z'' | −13.9 | 15.5 | 10.9 |
| Accruals ratio | −8.3% | −4.7% | −1.9% |
Source: SEC EDGAR XBRL filings (CIK 0001868279). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.